Myriad Genetics Inc (MYGN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $542.92M
Last updated: Nov 17, 2026 at 4:15 PM ET
Myriad Genetics Inc (MYGN) Statistics
Myriad Genetics (MYGN) has a market cap of $542.92M and an enterprise value of $556.92M. It kept -16.07% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 2.58% above the market cap, as debt exceeds cash.
| Market Cap | $542.92M |
|---|---|
| Enterprise Value | $556.92M |
| Latest price (Nov 17, 2026) | $5.54 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.7x and 2.0x. Its year-end P/S ranged from 0.7x to 3.3x from 2016 to 2025.
| P/S Ratio | 0.7x |
|---|---|
| Forward P/S | 0.7x |
| P/B Ratio | 2.0x |
| P/TBV Ratio | 5.9x |
Price Statistics
The stock is down 17.44% over 52 weeks and trades 14.46% above its 50-day average.
| Beta (1Y) | 0.63 |
|---|---|
| 52-Week Change | -17.44% |
| 1-Month Change | +31.59% |
| 3-Month Change | +73.67% |
| 6-Month Change | +56.06% |
| 5-Year Change | -79.36% |
| 10-Year Change | -67.78% |
| Total Return (1Y) | -17.44% |
| Total Return (3Y CAGR) | -32.31% |
| Total Return (5Y CAGR) | -27.86% |
| Return vs SPY (1Y) | -28.00% |
| Max Drawdown (1Y) | -63.84% |
| Max Drawdown (3Y) | -90.00% |
| Sharpe Ratio (1Y) | -0.19 |
| Correlation with SPY (1Y) | 0.09 |
| 50-Day Average | $4.84 |
| 200-Day Average | $4.61 |
| 52-Week Range | $2.74 to $8.09 |
| RSI (14 Days) | 51.3 |
| Average Volume (20 Days) | 2.09M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.98x current liabilities, and total debt is 0.45x shareholder equity.
| Current Ratio | 1.98x |
|---|---|
| Quick Ratio | 1.77x |
| Debt / Equity | 0.45x |
| Interest Coverage | -6.89x |
Returns and Efficiency
Return on invested capital is -29.46% over the last 12 months, against a 5-year average of -27.55%.
| Return on Equity (ROE) | -47.99% |
|---|---|
| Return on Assets (ROA) | -21.19% |
| Return on Invested Capital (ROIC) | -29.46% |
| Return on Capital Employed (ROCE) | -24.39% |
| ROE (5Y Average) | -33.33% |
| ROA (5Y Average) | -19.71% |
| ROIC (5Y Average) | -27.55% |
| Asset Turnover | 1.20x |
| Inventory Turnover | 8.60x |
| Receivables Turnover | 7.48x |
| Cash Conversion Cycle | 50 days |
Scores
MYGN has an Altman Z-Score of -0.96, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.96 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $803.60M over the last 12 months is down 2.63% from the 12 months before.
| Revenue | $803.60M |
|---|---|
| Revenue Growth (YoY) | -2.63% |
| Gross Profit | $549.10M |
| Operating Income | -$115.20M |
| Pretax Income | -$129.20M |
| Net Income | -$129.10M |
| EBITDA | -$64.80M |
| EBIT | -$115.00M |
| Reported EPS (TTM) | -$0.59 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 44.16% of the $609.20M in total assets.
| Cash and Equivalents | $107.10M |
|---|---|
| Total Debt | $121.10M |
| Net Debt | $14.00M |
| Net Debt Per Share | $0.15 |
| Working Capital | $134.30M |
| Shareholder Equity | $269.00M |
| Book Value Per Share | $2.81 |
| Tangible Book Value | $90.10M |
| Tangible Book Per Share | $0.94 |
| Total Assets | $609.20M |
| Total Liabilities | $340.20M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $14.00M of capital spending, operating cash flow left -$33.90M of free cash flow.
| Operating Cash Flow | -$19.90M |
|---|---|
| Capital Expenditures | $14.00M |
| Free Cash Flow | -$33.90M |
| FCF Per Share | -$0.35 |
| Depreciation and Amortization | $50.20M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -14.34%, against a 5-year average of -28.84%.
| Gross Margin | 68.33% |
|---|---|
| Operating Margin | -14.34% |
| Pretax Margin | -16.08% |
| Net Margin | -16.07% |
| EBITDA Margin | -8.06% |
| EBIT Margin | -14.31% |
| FCF Margin | -4.22% |
| Gross Margin (5Y Average) | 70.02% |
| Operating Margin (5Y Average) | -28.84% |
| Net Margin (5Y Average) | -23.00% |
Growth
Revenue grew 6.72% a year over 3 years.
| Revenue Growth (3Y CAGR) | +6.72% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -34.15% |
| Tangible Book Per Share Growth (2Y CAGR) | +1.40% |
Dividends and Yields
MYGN does not pay a dividend. Its free cash flow yield is -6.39%.
| FCF Yield | -6.39% |
|---|---|
| Buyback Yield | -0.11% |
| Shareholder Yield | -0.11% |
Stock Splits
The last split was a 2-for-1 forward split on Mar 26, 2009.
| Last Split Date | Mar 26, 2009 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 11 similar companies, MYGN has the lowest P/S.
P/S RatioPeer median 3.4x
ROICPeer median -5.68%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +17.18%
| P/S Ratio | 0.7x vs 3.4x median |
|---|---|
| ROIC | -29.46% vs -5.68% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -2.63% vs +17.18% median |
Analyst Forecast
Consensus estimates put revenue growth at -6.57% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -6.57% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MYGN
What is MYGN's market cap?
Myriad Genetics has a market cap of $542.92M. Its enterprise value, which adds debt and subtracts cash, is $556.92M.
How many shares of MYGN are outstanding?
Myriad Genetics has 95.70M shares outstanding. The count is up 2.79% from a year earlier.
Does MYGN pay a dividend?
No. Myriad Genetics does not pay a dividend.
How much debt does MYGN have?
Myriad Genetics has $121.10M of total debt and $107.10M of cash and equivalents, a net debt position of $14.00M.
MYGN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts